Compugen Ltd. · NASDAQ:CGEN
Compugen — Investor Presentation (February 2004)
28 slides from Compugen's investor presentation, February 2004
Slide 1: Compugen: Increasing the Probability of Success in Drug Discovery
Compugen: Increasing the Probability of Success in Drug Discovery February 2004
Slide 2: Agenda
Agenda • Introduction • Genomic Infrastructure • Discovery Engines: Therapeutic Proteins • Discovery Engines: Biomarkers • Lead Discovery • Summary
Slide 3: Compugen – A Few Facts
Compugen – A Few Facts • Founded 1993 • IPO August 2000 (Nasdaq: CGEN) • TASE since January 2002 • 150 employees • ~75% R&D, ~30% Ph.D. • Biology and Chemistry wet labs • Facilities: • Tel Aviv, Israel (Ltd. Hdqtrs) • Ashkelon, Israel (Chemistry Project) • Jamesburg, New Jersey (Inc. Hdqtrs) • Rockv
Slide 4: Financial Status
Financial Status (millions) 2000 2001 2002 2003 Revenues $7.4 $11.4 $11.1 $8.8 R&D Expenses $12.6 $16.0 $14.2 $13.3 Net loss $13.4 $15.1 $12.2 $11.4 Cash & equivalents $90.7 $78.5 $67.3 $60.5 Long-term debt. none none none none Fully diluted shares 29.8 31.3 31.1 31.8
Slide 5: Business Model
Business Model • Industry partnerships around core technologies • Licensing and collaborations with respect to specific discoveries – Internal focus on therapeutic proteins and biomarkers – Joint discovery collaborations
Slide 6: Short Term Plans
Short Term Plans • Platform collaborations • Scientific publications • Issuance of patents • Agreements for commercialization of therapeutic and diagnostic products
Slide 7: Probability Of Success (POS)
Probability Of Success (POS) • POS: The chances a given discovery will result in a product • Our mission – To increase the probability of success of drug and diagnostic development by incorporating ideas and methods from mathematics, computer science, and physics into the disciplines of biology, org
Slide 8: What We Do
What We Do • Build technologies that address POS- critical components in the drug discovery process • Current major technologies: – Genomic infrastructure platforms – Discovery engines: therapeutic proteins and biomarkers – Lead discovery technology
Slide 9: R&D Process
R&D Process Analysis, mathematical modeling, predictions Lab studies, Computational validation, Manual proof
Slide 10: Unique Structure
Unique Structure • Small teams comprised of biologists/chemists/physicians, mathematicians, and software developers work together side-by-side • Both biologists and mathematicians program and run experiments • No “bioinformatics services” group • Very fast development cycle
Slide 11: Agenda
Agenda • Introduction • Genomic Infrastructure • Discovery Engines: Therapeutic Proteins • Discovery Engines: Biomarkers • Lead Discovery • Summary
Slide 12: The LEADS Process
The LEADS Process • Computational biology platform • Used by, among others: • Unique modeling of biological phenomena
Slide 13: Biological Phenomena
Biological Phenomena • Discovered by applying mathematical modeling to public experimental data • Some key examples: – High frequency of alternative splicing – Thousands of sense-antisense gene pairs • Directly relevant to drug discovery – Additional targets
Slide 14: Alternative Splicing
Alternative Splicing Genome Res. July 2002 Science. May 2003 Genome Res. July 2003 Trends in Genetics. February 2004
Slide 15: Antisense
Antisense Sco
Slide 16: Agenda
Agenda • Introduction • Genomic Infrastructure • Discovery Engines: Therapeutic Proteins • Discovery Engines: Biomarkers • Lead Discovery • Summary
Slide 17: Discovery Engines Process
Discovery Engines Process Biological phenomena Engine monitored Engine and improved LEADS Models and Experts “Wet” queries Additional data Mining Novel proteins with desired features
Slide 18: Initial Pipeline
Initial Pipeline • Internal focus: therapeutic proteins and biomarkers • VEGF-114 • PSA-LM and K-LM • CGEN-40 • CGEN-G11 • CGEN-B2
Slide 19: VEGF-114
VEGF-114 • Shortest known variant of VEGF • Patent granted • Licensed to MultiGene Vascular Systems (MGVS) for gene and cell therapy in cardiovascular disease • Further validated by MGVS
Slide 20: Agenda
Agenda • Introduction • Genomic Infrastructure • Discovery Engines: Therapeutic Proteins • Discovery Engines: Biomarkers • Lead Discovery • Summary
Slide 21: Cancer Biomarker Engine
Cancer Biomarker Engine Dry analysis Wet analysis Dry Oligo Identify Microarray Analysis design candidates over- expressed in cancer Quantitative IP RT-PCR Initially validated novel markers
Slide 22: PSA-LM and K-LM
Scientific Leadership PSA-LM and K-LM Licensed to DPC J Biol Chem. 2002 May 17;277(20):18084-90
Slide 23: Agenda
Agenda • Introduction • Genomic Infrastructure • Discovery Engines: Therapeutic Proteins • Discovery Engines: Biomarkers • Lead Discovery • Summary
Slide 24: Approach in Brief
Approach in Brief • Design and build a library containing a complete set of small molecules that theoretically complement any/all active sites – <100,000 novel compounds – Not drug-like molecules – One-time effort • Screen target with library • Analyze results, reconstruct active site – Design of li
Slide 25: Advantages
Advantages • Potentially, drug leads for any target • No structure information required • Relatively small yet exhaustive screening library • Great flexibility in design of leads
Slide 26: Agenda
Agenda • Introduction • Genomic Infrastructure • Discovery Engines: Therapeutic Proteins • Discovery Engines: Biomarkers • Lead Discovery • Summary
Slide 27: Summary
Summary • Increasing POS of drug discovery through: – Mathematical models and algorithmic approach – Processes that integrate “dry” and “wet” – A better understanding of biological phenomena – Iterative improvements to processes • Quickly established attractive pipeline of therapeutic proteins and b
Slide 28: Compugen: Increasing the Probability of Success in Drug Discovery
Compugen: Increasing the Probability of Success in Drug Discovery February 2004